ELEV Stock Price, Elevation Oncology, Inc. Quote, Chart

Market Summary

USD3.63+0.02

Delayed

0.55%

ELEV Stock Price

View Fullscreen

ELEV RSI Chart

ELEV Valuation

Market Cap

198.3M

Price/Earnings (Trailing)

-5.04

EV/EBITDA

-3.87

Price/Free Cashflow

-4.05

MarketCap/EBT

-5.04

ELEV Price/Earnings (Trailing)

ELEV Profitability

Return on Equity

-51.9%

Return on Assets

-36.12%

Free Cashflow Yield

-24.67%

ELEV Fundamentals

ELEV Earnings

Earnings (TTM)

-39.4M

Earnings Growth (Yr)

37.24%

Earnings Growth (Qtr)

-35.55%

Breaking Down ELEV Revenue

Last 7 days

10.7%

Last 30 days

-12.3%

Last 90 days

23.1%

Trailing 12 Months

-28.3%

How does ELEV drawdown profile look like?

ELEV Financial Health

Current Ratio

46.22

Debt/Equity

0.41

Debt/Cashflow

-1.59

ELEV Investor Care

Shares Dilution (1Y)

124.50%

Diluted EPS (TTM)

-0.92

Tracking the Latest Insider Buys and Sells of Elevation Oncology, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 16, 2024	ferra joseph j jr	sold (taxes)	-20,953	4.39	-4,773	chief executive officer
Mar 16, 2024	ferra joseph j jr	acquired	-	-	12,562	chief executive officer
Feb 15, 2024	furlong tammy	sold (taxes)	-1,116	2.77	-403	chief financial officer
Feb 15, 2024	furlong tammy	acquired	-	-	1,200	chief financial officer
Dec 16, 2023	ferra joseph j jr	sold (taxes)	-2,434	0.51	-4,773	chief executive officer
Dec 16, 2023	ferra joseph j jr	acquired	-	-	12,563	chief executive officer
Sep 16, 2023	ferra joseph j jr	sold (taxes)	-3,474	0.728	-4,773	chief executive officer
Sep 16, 2023	ferra joseph j jr	acquired	-	-	12,562	chief executive officer
Sep 01, 2023	clackson timothy p	gifted	-	-	-15,777	-
Jun 16, 2023	ferra joseph j jr	sold (taxes)	-7,016	1.47	-4,773	interim ceo & cfo

Which funds bought or sold ELEV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	404,757	404,757	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-195,947	-	-%
May 15, 2024	Point72 Asset Management, L.P.	new	-	17,278,900	17,278,900	0.04%
May 15, 2024	CITADEL ADVISORS LLC	added	165	7,734,240	8,051,860	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	new	-	2,827,040	2,827,040	-%
May 15, 2024	FARALLON CAPITAL MANAGEMENT LLC	new	-	19,938,600	19,938,600	0.09%
May 15, 2024	Royal Bank of Canada	sold off	-100	-	-	-%
May 15, 2024	ORBIMED ADVISORS LLC	reduced	-37.25	4,023,240	4,828,740	0.09%
May 15, 2024	BVF INC/IL	unchanged	-	10,619,900	11,861,600	0.33%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	new	-	546,345	546,345	0.01%

Are Funds Buying or Selling ELEV?

Are funds buying ELEV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ELEV

No. of Funds

Unveiling Elevation Oncology, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 09, 2024	frazier life sciences public fund, l.p.	3.1%	1,486,390	SC 13G
Feb 14, 2024	k2 healthventures equity trust llc	4.0%	1,784,169	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	7.5%	3,344,177	SC 13G/A
Feb 14, 2024	point72 asset management, l.p.	9.4%	4,040,000	SC 13G/A
Feb 14, 2024	cormorant asset management, lp	0.00%	0	SC 13G/A
Feb 14, 2024	tang capital partners lp	9.99%	4,300,454	SC 13G/A
Feb 14, 2024	orbimed advisors llc	6.8%	3e+06	SC 13G
Feb 07, 2024	exoduspoint capital management, lp	0.1%	50,000	SC 13G/A
Feb 06, 2024	aisling capital iv, lp	6.8%	2,878,296	SC 13G/A
Jan 31, 2024	integrated core strategies (us) llc	7.0%	2,957,348	SC 13G/A

Recent SEC filings of Elevation Oncology, Inc.

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 09, 2024	EFFECT	EFFECT
May 09, 2024	424B3	Prospectus Filed
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
May 02, 2024	S-3	S-3
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 09, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Elevation Oncology, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Elevation Oncology, Inc. News

Latest updates

Elevation Oncology, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	22.3%	109	89.00	100	110	77.00	94.00	111	124	134	149	159	159	81.00
Current Assets	22.6%	108	88.00	99.00	109	76.00	93.00	110	124	134	149	158	159	81.00
Cash Equivalents	84.0%	91.00	49.00	55.00	106	56.00	46.00	53.00	54.00	53.00	146	155	158	79.00
Net PPE	-16.9%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-3.3%	33.00	34.00	38.00	38.00	43.00	45.00	44.00	19.00	10.00	9.00	9.00	4.00	7.00
Current Liabilities	-43.7%	2.00	4.00	8.00	8.00	14.00	16.00	15.00	19.00	10.00	9.00	9.00	4.00	7.00
Long Term Debt	2.2%	31.00	30.00	30.00	30.00	30.00	29.00	29.00	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	30.00	30.00	30.00	30.00	29.00	29.00	-	-	-	-	-	-
Shareholder's Equity	38.3%	76.00	55.00	62.00	72.00	34.00	49.00	67.00	105	124	141	150	155	-
Retained Earnings	-5.4%	-206	-196	-188	-177	-167	-150	-131	-92.40	-72.46	-55.19	-45.56	-33.30	-23.15
Additional Paid-In Capital	12.7%	283	251	251	250	201	199	199	197	197	196	195	189	0.00
Shares Outstanding	21.8%	52.00	42.00	42.00	42.00	24.00	23.00	23.00	23.00	23.00	23.00	23.00	-	-
Float	-	-	-	-	53.00	-	-	-	22.00	-	-	-	211	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	21.4%	-9,575	-12,181	-13,357	-13,811	-16,831	-17,849	-44,183	-9,427	-14,024	-8,914	-7,904	-3,872	-9,477	-	-	-
Share Based Compensation	217.6%	902	284	843	744	1,464	859	883	837	627	689	659	158	65.00	-	-	-
Cashflow From Investing	215.5%	20,700	6,560	-38,117	16,500	26,600	11,181	13,366	10,326	-79,271	-	-	-	-	-	-	-
Cashflow From Financing	1512600.0%	30,250	-2.00	27.00	47,734	216	-4.00	29,524	-25.00	19.00	-	5,085	91,977	-11.00	-	-	-
Buy Backs	1200.0%	26.00	2.00	3.00	7.00	12.00	4.00	6.00	25.00	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ELEV Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 6,011	$ 7,292
General and administrative	3,858	4,346
Restructuring charges	0	5,107
Total operating expenses	9,869	16,745
Loss from operations	(9,869)	(16,745)
Interest income (expense), net	115	(309)
Loss on extinguishment of debt	(942)	0
Total other income (expense), net	(827)	(309)
Loss before income taxes	(10,696)	(17,054)
Income tax expense	11	5
Net loss	$ (10,707)	$ (17,059)
Net Loss Per Share
Net loss per share, basic (in dollars per share)	$ (0.23)	$ (0.72)
Net loss per share, diluted (in dollars per share)	$ (0.23)	$ (0.72)
Weighted average common shares outstanding, basic (in shares)	47,371,882	23,618,559
Weighted average common shares outstanding, diluted (in shares)	47,371,882	23,618,559
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	$ (9)	$ 110
Total other comprehensive income (loss)	(9)	110
Total comprehensive loss	$ (10,716)	$ (16,949)

ELEV Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 90,630	$ 49,255
Marketable securities, available for sale	13,421	33,852
Prepaid expenses and other current assets	3,836	4,857
Total current assets	107,887	87,964
Property and equipment, net	49	59
Other non-current assets	1,025	1,068
Total assets	108,961	89,091
Current liabilities:
Accounts payable	435	507
Accrued expenses	1,899	3,638
Total current liabilities	2,334	4,145
Non-current liabilities:
Long-term debt, net of discount	30,809	30,137
Total liabilities	33,143	34,282
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued or outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; 500,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; 51,732,292 and 42,470,264 shares issued as of March 31, 2024 and December 31, 2023, respectively; 51,679,383 and 42,422,531 shares outstanding as of March 31, 2024 and December 31, 2023, respectively	5	4
Additional paid-in capital	282,575	250,825
Accumulated other comprehensive income (loss)	0	9
Treasury stock, 52,909 and 47,733 shares as of March 31, 2024 and December 31, 2023, respectively; at cost	(85)	(59)
Accumulated deficit	(206,677)	(195,970)
Total stockholders' equity	75,818	54,809
Total liabilities and stockholders' equity	$ 108,961	$ 89,091

About Elevation Oncology, Inc.

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in New York, New York.

CEO	Mr. Joseph J. Ferra Jr.
WEBSITE	https://elevationoncology.com
INDUSTRY	Biotechnology
EMPLOYEES	33

Elevation Oncology, Inc. Frequently Asked Questions

What is the ticker symbol for Elevation Oncology, Inc.? What does ELEV stand for in stocks?

ELEV is the stock ticker symbol of Elevation Oncology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Elevation Oncology, Inc. (ELEV)?

As of Fri May 17 2024, market cap of Elevation Oncology, Inc. is 198.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ELEV stock?

You can check ELEV's fair value in chart for subscribers.

What is the fair value of ELEV stock?

You can check ELEV's fair value in chart for subscribers. The fair value of Elevation Oncology, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Elevation Oncology, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ELEV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Elevation Oncology, Inc. a good stock to buy?

The fair value guage provides a quick view whether ELEV is over valued or under valued. Whether Elevation Oncology, Inc. is cheap or expensive depends on the assumptions which impact Elevation Oncology, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ELEV.

What is 5 year return on Elevation Oncology, Inc.'s stock?

In the past 10 years, Elevation Oncology, Inc. has provided 0.623 (multiply by 100 for percentage) rate of return.